Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning,First-In-Class NeurophysiologyPlatform for At-Home Use
User-friendly electroencephalogram (EEG) synced device enables self-directed use and generates clinical-grade data forremote physician review.
Leadership team expands with appointment of industry veteran Tina Sampath as Chief Commercial Officer.
BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; TheCompany), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced that its novel, award-winning dry-sensor EEG headset, has been granted 510(k) clearance from the United States Food and Drug Administration (FDA). This represents the second medical device clearance for theheadset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.
Designed for self-directed use in a patient’s home or a healthcare facility, the Cumulus EEG device is now FDA-cleared for useby adult and adolescent patients for the remote acquisition, display, and storage of electroencephalograph (EEG) data. Theheadset is available in four sizes, and is easily self-applied in less than five minutes with guidance from the Cumulus mobileapp – eliminating the need for EEG technician or healthcare professional support. This groundbreaking technology provides ameans to initiate clinical studies remotely with data transmitted to the Cumulus Medical Device Hub, allowing healthcareprofessionals to review EEG recordings in real-time.
“Receiving 510(k) clearance from the FDA marks a major milestone for Cumulus, and for our biopharma innovator partners inthe US and Europe who need the ability to capture clinical-grade, EEG signals from patients while at-home, to accelerate theirdevelopment programs for precision CNS medicines,” said Brian Murphy, Founder and Chief Scientific Officer, CumulusNeuroscience. “By providing reliable data across multiple domains of brain function, from specific disease symptoms tofunctional neurophysiology, clinical researchers can accelerate the development of treatments for neuropsychiatric andneurodegenerative disorders – bringing hope to millions of patients and families navigating unmet needs in the CNSecosystem.”
The company’s 510(k) clearance comes on the heels of its appointment of Tina Sampath as Chief Commercial Officer (CCO).An award-winning marketing executive with a proven track record of creating growth and profitability through data-driven,integrated, cross-channel marketing strategies, Sampath brings more than 23 years of commercial leadership experience atwell-known biopharma, diagnostic and med tech companies, including Gilead Sciences (via $1.4B acquisition of CVTherapeutics 2009), Pfizer (via $14B acquisition of Medivation in 2016) and AliveCor. Sampath was also essential in the BraccoImaging acquisition of Blue Earth Diagnostics for $450M in 2019. With new and growing biopharma collaborations underway, the establishment of offices in the Boston area at the new Cambridge Innovation Center (CIC), and now, FDAclearance for the Cumulus Platform, Sampath is charged with driving commercial growth, while overseeing strategicpartnerships, marketing operations and corporate communications.
“Becoming FDA-cleared is another gratifying leap forward for Cumulus, as we work to become the preferred precision CNSdrug development partner for biopharma innovators and advance the possibilities for new treatments for neuropsychologicaldisorders,” said Aman Bhatti, MD, CEO, Cumulus Neuroscience. “A user-friendly EEG device that patients can apply themselvesat home opens significant doors for decentralized clinical trials and remote patient monitoring, and with that, the possibilityof improved diversity in clinical research that can lead to better data and outcomes. The fact that FDA clearance coincideswith our recent design awards and Tina joining our executive team is incredibly exciting, and positions Cumulus for significantgrowth as we pursue our mission of accelerating precision treatments for and diagnosis of CNS disorders.”
Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients acrossmultiple domains of brain function. To learn more, visit www.cumulusneuro.com.
Notes to Editors
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system(CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based,multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinicaltrials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enablesdecentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depressionand schizophrenia.